MX2023008196A - Anticuerpos anti-n3pglu beta amiloide y usos de estos. - Google Patents
Anticuerpos anti-n3pglu beta amiloide y usos de estos.Info
- Publication number
- MX2023008196A MX2023008196A MX2023008196A MX2023008196A MX2023008196A MX 2023008196 A MX2023008196 A MX 2023008196A MX 2023008196 A MX2023008196 A MX 2023008196A MX 2023008196 A MX2023008196 A MX 2023008196A MX 2023008196 A MX2023008196 A MX 2023008196A
- Authority
- MX
- Mexico
- Prior art keywords
- n3pglu
- amyloid beta
- antibodies
- beta antibodies
- brain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Compounds Of Unknown Constitution (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163135932P | 2021-01-11 | 2021-01-11 | |
| US202163155029P | 2021-03-01 | 2021-03-01 | |
| US202163160380P | 2021-03-12 | 2021-03-12 | |
| US202163192262P | 2021-05-24 | 2021-05-24 | |
| US202163227054P | 2021-07-29 | 2021-07-29 | |
| US202163277298P | 2021-11-09 | 2021-11-09 | |
| US202163284248P | 2021-11-30 | 2021-11-30 | |
| US202263296694P | 2022-01-05 | 2022-01-05 | |
| PCT/US2022/011894 WO2022150735A1 (en) | 2021-01-11 | 2022-01-11 | Anti-n3pglu amyloid beta antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023008196A true MX2023008196A (es) | 2023-07-18 |
Family
ID=80123357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023008196A MX2023008196A (es) | 2021-01-11 | 2022-01-11 | Anticuerpos anti-n3pglu beta amiloide y usos de estos. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20240010713A1 (https=) |
| EP (1) | EP4274611A1 (https=) |
| JP (2) | JP7676556B2 (https=) |
| KR (2) | KR20260047659A (https=) |
| AU (1) | AU2022206461B2 (https=) |
| CA (1) | CA3204444A1 (https=) |
| CL (1) | CL2023001992A1 (https=) |
| CO (1) | CO2023009089A2 (https=) |
| EC (1) | ECSP23051813A (https=) |
| IL (1) | IL304072A (https=) |
| MX (1) | MX2023008196A (https=) |
| PE (1) | PE20231748A1 (https=) |
| TW (1) | TWI843040B (https=) |
| WO (1) | WO2022150735A1 (https=) |
| ZA (1) | ZA202306180B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022307687A1 (en) * | 2021-07-09 | 2024-01-04 | Eisai R&D Management Co., Ltd. | Biomarkers for alzheimer's disease treatment |
| WO2023039107A2 (en) | 2021-09-09 | 2023-03-16 | Alzpath, Inc. | Phospho-tau antibodies and methods of use |
| CA3243602A1 (en) * | 2022-02-03 | 2023-08-10 | Eli Lilly And Company | Regional Tau Imaging for the Diagnosis and Treatment of Alzheimer's Disease |
| KR20250107906A (ko) * | 2022-11-17 | 2025-07-14 | 일라이 릴리 앤드 캄파니 | 항-N3pGlu 아밀로이드 베타 항체, 그의 용량 및 용도 |
| KR20250173598A (ko) * | 2023-03-16 | 2025-12-10 | 알즈패스, 인크. | 신경퇴행성 질환의 진단 및 치료 방법 |
| WO2025231343A1 (en) * | 2024-05-03 | 2025-11-06 | Therini Bio, Inc. | Doses of antibodies which bind human fibrin yc or fibrinogen yc domain for neurodegenerative diseases |
| WO2025240435A1 (en) * | 2024-05-14 | 2025-11-20 | Othair Prothena Limited | Methods of treating neurological disorders with anti-abeta antibodies |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1257584T1 (de) | 2000-02-24 | 2003-05-28 | Lilly Co Eli | Humanisierte antikörper, die amyloid beta peptid demarkieren |
| PT1944040E (pt) | 2001-08-17 | 2012-10-31 | Univ Washington | Método de avaliação para a doença de alzheimer |
| SI1720909T1 (sl) | 2004-02-23 | 2012-01-31 | Lilly Co Eli | Anti-abeta protitelo |
| WO2010009987A2 (en) | 2008-07-21 | 2010-01-28 | Probiodrug Ag | Diagnostic antibody assay |
| WO2011151076A2 (en) | 2010-06-04 | 2011-12-08 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS |
| PL3042917T3 (pl) | 2010-08-12 | 2018-07-31 | Eli Lilly And Company | Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie |
| WO2012021475A2 (en) * | 2010-08-12 | 2012-02-16 | Eli Lilly And Company | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
| US9499610B2 (en) | 2011-04-08 | 2016-11-22 | H. Lundbeck A/S | Antibodies specific to pyroglutamated Aβ |
| JOP20170004B1 (ar) | 2016-01-15 | 2022-09-15 | Lilly Co Eli | الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته |
| TWI798751B (zh) * | 2016-07-01 | 2023-04-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| TWI789644B (zh) | 2017-04-20 | 2023-01-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| CN107289872A (zh) | 2017-06-28 | 2017-10-24 | 京东方科技集团股份有限公司 | 测高装置 |
| KR102905634B1 (ko) | 2019-05-31 | 2025-12-30 | 일라이 릴리 앤드 캄파니 | 인간 타우를 표적화하는 화합물 및 방법 |
-
2022
- 2022-01-10 TW TW111101008A patent/TWI843040B/zh active
- 2022-01-11 IL IL304072A patent/IL304072A/en unknown
- 2022-01-11 KR KR1020267008447A patent/KR20260047659A/ko active Pending
- 2022-01-11 AU AU2022206461A patent/AU2022206461B2/en active Active
- 2022-01-11 CA CA3204444A patent/CA3204444A1/en active Pending
- 2022-01-11 WO PCT/US2022/011894 patent/WO2022150735A1/en not_active Ceased
- 2022-01-11 JP JP2023541749A patent/JP7676556B2/ja active Active
- 2022-01-11 US US18/260,125 patent/US20240010713A1/en active Pending
- 2022-01-11 EP EP22701816.5A patent/EP4274611A1/en active Pending
- 2022-01-11 KR KR1020237027055A patent/KR102942744B1/ko active Active
- 2022-01-11 MX MX2023008196A patent/MX2023008196A/es unknown
- 2022-01-11 PE PE2023002030A patent/PE20231748A1/es unknown
-
2023
- 2023-06-12 ZA ZA2023/06180A patent/ZA202306180B/en unknown
- 2023-07-06 CL CL2023001992A patent/CL2023001992A1/es unknown
- 2023-07-07 CO CONC2023/0009089A patent/CO2023009089A2/es unknown
- 2023-07-10 EC ECSENADI202351813A patent/ECSP23051813A/es unknown
-
2025
- 2025-04-30 JP JP2025075147A patent/JP2025131566A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TWI843040B (zh) | 2024-05-21 |
| AU2022206461A1 (en) | 2023-06-29 |
| ZA202306180B (en) | 2025-02-26 |
| PE20231748A1 (es) | 2023-11-06 |
| TW202243690A (zh) | 2022-11-16 |
| IL304072A (en) | 2023-08-01 |
| KR20260047659A (ko) | 2026-04-08 |
| CA3204444A1 (en) | 2022-07-14 |
| WO2022150735A1 (en) | 2022-07-14 |
| KR20230130695A (ko) | 2023-09-12 |
| EP4274611A1 (en) | 2023-11-15 |
| CO2023009089A2 (es) | 2023-09-29 |
| KR102942744B1 (ko) | 2026-03-23 |
| JP7676556B2 (ja) | 2025-05-14 |
| CL2023001992A1 (es) | 2024-02-02 |
| US20240010713A1 (en) | 2024-01-11 |
| JP2025131566A (ja) | 2025-09-09 |
| JP2024503025A (ja) | 2024-01-24 |
| AU2022206461B2 (en) | 2026-02-05 |
| ECSP23051813A (es) | 2023-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023008196A (es) | Anticuerpos anti-n3pglu beta amiloide y usos de estos. | |
| MX2023010625A (es) | Anticuerpos anti-beta amiloide y usos de estos. | |
| EP4001277A3 (en) | Bicyclic compounds for diagnosis and therapy | |
| Park et al. | The effects of mirror therapy with tasks on upper extremity function and self-care in stroke patients | |
| MX2022008181A (es) | Composiciones farmaceuticas que comprenden un compuesto de dextrometorfano y quinidina para el tratamiento de agitacion en demencia. | |
| EA201892690A1 (ru) | АНТИТЕЛА К БЕТА-АМИЛОИДНОМУ ПЕПТИДУ N3pGlu И ИХ ПРИМЕНЕНИЕ | |
| EA201791199A1 (ru) | Способ лечения болезни альцгеймера | |
| MX2025001920A (es) | Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina | |
| EA201991078A1 (ru) | Креноланиб для лечения пролиферативных расстройств, связанных с мутацией flt3 | |
| BR112021024633A2 (pt) | Composições e métodos que usam trigonelina e vitaminas para evitar ou tratar condições ou distúrbios no músculo esquelético | |
| EA200700427A1 (ru) | Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний | |
| PH12021552677A1 (en) | Beta-1,3'-galactosyllactose for the treatment of gut barrier function diseases | |
| EA202090242A1 (ru) | Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов | |
| Lee et al. | Efficacy between Hwangryunhaedok-tang Pharmacopuncture Therapy and Hominis Placenta Pharmacopuncture Therapy on Peripheral Facial Paralysis: Retrospective Comparision Study | |
| Kunze et al. | Magnesium protects in episodes of critical perfusion after aneurysmal SAH | |
| BR112023021235A2 (pt) | Formas cocristalinas de um inibidor da tirosina quinase de bruton | |
| Peters et al. | Acquired stuttering due to recurrent anaplastic astrocytoma | |
| MX2022011879A (es) | Derivados de trapidilo marcados isotopicamente. | |
| Hou et al. | Electroacupuncture combined with wet compress formula ameliorates upper limb dysfunction associated with stroke: A retrospective analysis of 126 cases | |
| Bano et al. | Effectiveness of melatonin supplementation in preventing cognitive decline among older adults with sleep disorders: a narrative review | |
| Lee | Case reports on 70 Tic disorder cases managed with functional cerebrospinal therapy (FCST) | |
| EP4284361A4 (en) | Novel formulation for treating copper metabolism-associated diseases or disorders | |
| Park et al. | A case study of soeumin greater yin symptomatology patient diagnosed as cerebellar ataxia | |
| Wang et al. | To assess the Ginkgo biloba extracts and vestibular rehabilitation training for improving prognosis in vestibular neuritis. | |
| AU2020360413A8 (en) | Methods of treating conditions related to the S1P1 receptor |